Ocular complications of rheumatic diseases

Hart, Colby; Ferdinands, Merv; Barnsley, Leslie

doi:10.5694/mja16.00352

ARTICLE
AUTHORS
REFERENCES

Topics

Eye diseases

Summary

Rheumatic diseases are frequently complicated by extra-articular manifestations, often affecting the eye.
Most of these ocular symptoms are benign and develop over long periods of time.
Some ocular complications of rheumatic disease or the drugs used to treat the disease are rapidly sight-threatening.
It is vital that sight-threatening complications are recognised quickly, so that appropriate diagnostic and therapeutic procedures, such as slit lamp examination and the initiation of immunosuppressive treatments, can occur in a timely fashion.
Insight into the epidemiology, clinical presentation, common complications and treatment regimens of these ocular manifestations enables early detection and may prevent permanent loss of vision.

1 Alfred Health, Melbourne, VIC
2 Ophthalmology, Barwon Health, Geelong, VIC
3 Rheumatology, Concord Repatriation General Hospital, Sydney, NSW

Correspondence: colbyhart07@gmail.com

Acknowledgements:

We thank the Royal Victorian Eye and Ear Hospital for providing the images used in this article. All images are copyright MedPIC, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.

Competing interests:

No relevant disclosures.

1. Hamideh F, Prete PE. Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum 2001; 30: 217-241.
2. Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine 2007; 86: 61-68.
3. Waldman CW, Waldman SD, Waldman RA. Giant cell arteritis. Med Clin North Am 2013; 97: 329-335.
4. Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998; 125: 509-520.
5. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997; 123: 285-296.
6. Martinez-Taboada V, Blanco R, Armona J, et al. Giant cell arteritis with an erythrocyte sedimentation rate lower than 50. Clin Rheumatol 2000; 19: 73-75.
7. Chan C, Paine M, O’Day J. Steroid management in giant cell arteritis. Br J Ophthalmol 2001; 85: 1061-1064.
8. Sivaraj R, Durrani O, Denniston A, et al. Ocular manifestations of systemic lupus erythematosus. Rheumatology 2007; 46: 1757-1762.
9. Ermakova N, Alekberova Z. [Retinal vasculitis in Behcet’s disease] [Russian]. Vestn Oftalmol 2001; 117: 44-46.
10. Yagci A. Update on peripheral ulcerative keratitis. Clin Ophthalmol 2012; 6: 747-754.
11. Watanabe R, Ishii T, Yoshida M, et al. Ulcerative keratitis in patients with rheumatoid arthritis in the modern biologic era: a series of eight cases and literature review. Int J Rheum Dis 2015; doi: 10.1111/1756-185X.12688 [Epub ahead of print].
12. Bettero RG, Cebrian RFM, Skare TL. Prevalence of ocular manifestation in 198 patients with rheumatoid arthritis: a retrospective study. Arq Bras Oftalmol 2008; 71: 365-369.
13. Akpek EK, Thorne JE, Qazi FA, et al. Evaluation of patients with scleritis for systemic disease. Ophthalmology 2004; 111: 501-506.
14. Smith JR, Mackensen F, Rosenbaum JT. Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol 2007; 3: 219-226.
15. Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. Surv Ophthalmol 2005; 50: 351-363.
16. Suttorp-Schulten M, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996; 80: 844-848.
17. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516.
18. Monnet D, Breban M, Hudry C, et al. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology 2004; 111: 802-809.
19. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol 2005; 50: 364-388.
20. Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006; 113: 1446-1449.
21. Mavragani CP, Fragoulis GE, Moutsopoulos HM. Sjogren’s syndrome. In: Rose NR, Mackay IR, editors. The autoimmune diseases. San Diego, CA: Academic Press, 2012.
22. Andonopoulos A, Drosos A, Skopouli F, et al. Secondary Sjogren’s syndrome in rheumatoid arthritis. J Rheumatol 1987; 14: 1098-1103.
23. Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 907-927.
24. Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjögren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren’s syndrome. Arthritis Rheum 2004; 50: 882-891.
25. Papiris S, Tsonis I, Moutsopoulos H. Sjögren’s syndrome. Semin Respir Crit Care Med 2007; 28: 459-471.
26. Manthorpe R, Asmussen K, Oxholm P. Primary Sjögren’s syndrome: diagnostic criteria, clinical features, and disease activity. J Rheumatol Suppl 1997; 50: 8-11.
27. Carsons S. A review and update of Sjogren’s syndrome: manifestations, diagnosis, and treatment. Am J Manag Care 2001; 7 (14 Suppl): S433-S443.
28. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med 2004; 164: 1275-1284.
29. Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999; 15: 439-450.
30. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000; 11: 478-483.
31. National Health and Medical Research Council. NHMRC guidelines for the screening, prognosis, diagnosis, management and prevention of glaucoma. Canberra: NHMRC, 2010.
32. Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol 2004; 15: 541-548.
33. Peponis V, Kyttaris V, Chalkiadakis S, et al. Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. Lupus 2010; 19: 675-682.
34. Panday VA, Rhee DJ. Review of sulfonamide-induced acute myopia and acute bilateral angle-closure glaucoma. Compr Ophthalmol Update 2007; 8: 271-276.
35. Yam J, Kwok A. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006; 12: 294-304.
36. Marmor MF, Kellner U, Lai TYY, et al; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016; 123: 1386-1394.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Ocular complications of rheumatic diseases

Topics

Summary

Author

Comment

Do you have any competing interests to declare? *